Navigation Links
Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex

tent and selective FLT3 receptor tyrosine kinase inhibitors in vitro. Symadex is currently in Phase 2 clinical trials in oncology indications. Xanthus is also exploring the use of Symadex for the treatment of a number of autoimmune diseases, where early preclinical data has shown encouraging signs of activity.

About Xanthus Pharmaceuticals, Inc.

Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule therapeutic candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise to advance its current pipeline to address significant unmet medical need in oncology and autoimmune diseases.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at www.xanthus.com.

This press release contains forward-looking statements concerning Xanthus that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Xanthus' actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether results obtained in early clinical studies or in preclinical studies such as the studies referred to above will be indicative of results obtained in future clinical trials or warrant additional trials; whether products based on Xanthus' technology will advance through the clinical trial process and receive approval from the United States Food and Drug A
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition ... and Forecasts, 2012-2018"  report to their offering. Global ... 2016. The North America accounts ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, ... it has been added to the NASDAQ Biotechnology ... Index will become effective upon market open on ... Index is designed to track the performance of ... as either biotechnology or pharmaceutical according to the ...
(Date:12/15/2014)... 2014 Investor-Edge has initiated coverage on ... Eli Lilly and Company (NYSE: LLY ), Nektar ... SNY ), and Novartis AG (NYSE: NVS ). ... http://investor-edge.com/register . On Friday, December 12, 2014, ... Jones Industrial Average lost 1.79%, to finish the day at ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5
... That Include Important Clues,Toward the Development of Customized ... New findings from,research supported by NARSAD, the world,s ... by Harvard-affiliated scientists are,providing important clues into how ... and perception -- the behaviors associated with many,psychiatric ...
... old with diffuse,pontine glioma compared to older children suggests ... in young patients, MEMPHIS, Tenn., May 29 ... under 3 years old,who have a brain tumor called ... than older children with the same cancer., Results ...
Cached Medicine Technology:NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression 2NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression 3NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression 4NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression 5NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression 6St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 2St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 3
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... high levels of air pollution late in pregnancy may have ... Researchers found that of nearly 1,800 U.S. women who ... most air pollution during pregnancy were twice as likely to ... the third trimester, specifically, showed the strongest correlation to autism ...
(Date:12/19/2014)... News) -- Traveling through the same U.S. airport gate, ... others within a four-hour time span, illustrating just how ... "The exposures in this report were not prolonged ... terminal, highlighting the fact that measles is highly contagious," ... disease specialist at the U.S. Centers for Disease Control ...
(Date:12/19/2014)... By Steven Reinberg ... -- If you can,t balance on one leg for at ... stroke, Japanese researchers suggest. Difficulty standing on one leg ... occurred, which means the risk for more serious strokes is ... Stroke . "Individuals showing instability while standing on ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Futureā€ and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... 2014 This prestigious award is ... have made outstanding and innovative contributions to the ... of private practice physical therapy by the Private ... , On behalf of Performance Physical Therapy, Michelle ... of Performance accepted the award at the Private ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... cue to safety; group seeks legislative help , , MONDAY, ... silent, hybrid cars pose a serious threat of injury and ... Council of the Blind, which is pushing the auto industry ... , "Traditionally, people who are blind or visually impaired learn ...
... (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection (CAD),solutions, ... to purchase the principal assets of CAD Sciences, ... NY. The,purchase price was $5 million, comprised of ... common stock. The number of shares issued was,calculated ...
... and Weight Management ... ... in applying advanced technology to emulate a health coaching,session via the ... and medication adherence, is launching HealthMedia(R),Overcoming(TM) Binge Eating. This revolutionary new ...
... Fidelity National,Financial, Inc. (NYSE: FNF ), ... management services and information services,today announced the opening ... Title de Mexico S.A. de C.V. ("Fidelity Title ... Vice President and General,Manager and Gerardo Martinez has ...
... July 21 Mylan Inc. (NYSE: MYL ... as vice president -,Investor Relations and as a ... Chief Financial Officer Edward J. Borkowski, Crookshank is,responsible ... for the,development and direction of activities that proactively ...
... and OTTAWA, July 21 iNutrition, Inc, ... ) subsidiaries of Natural Nutrition, Inc, (OTC,Bulletin ... have inked an,agreement with actor John O,Hurley ... be celebrity endorser and spokesman for the ...
Cached Medicine News:Health News:Hybrid Cars Pose Risk to Blind, Visually Impaired 2Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 3Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 4Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 2Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 3Health News:Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations 2Health News:iNutrition Signs John O'Hurley to Launch New Internet Video Campaign 2
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of phenytoin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartrid...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
... The Emit 2000 Digoxin Assay ... intended for use in the ... human serum or plasma. Kits ... on the Roche COBAS MIRA, ...
Medicine Products: